Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society

被引:37
作者
Lebrun, Christine [1 ]
Vukusic, Sandra [2 ,3 ,4 ,5 ,6 ]
Lebrun-frenay, Christine
De Seze, Jerome
Ayrignac, Xavier
Bensa, Caroline
Le Page, Emmanuelle
Ouallet, Jean-Christophe
Thouvenot, Eric
Zephir, Helene
Bourre, Bertrand
Casez, Olivier
Ciron, Jonathan
Cohen, Mikael
Collongues, Nicolas
Davenas, Charlotte
Derache, Nathalie
Guennoc, Anne Marie
Hadhoum, Nawal
Louapre, Celine
Maarouf, Adil
Mathey, Guillaume
Michel, Laure
Maillart, Elisabeth
Pittion, Sophie
Ruet, Aurelie
Wiertlewski, Sandrine
Audoin, Bertrand
Berger, Eric
Bernady, Patricia
Brassat, David
Brochet, Bruno
Cabre, Philippe
Camdessanche, Jean Philippe
Coustans, Marc
Debouverie, Marc
Edan, Gilles
Elias, Zyiad
Faucheux, Jean Marc
Gout, Olivier
Hautecoeur, Patrick
Heinzlef, Olivier
Labauge, Pierre
Laplaud, David
Leray, Emmanuelle
Magy, Laurent
Mekies, Claude
Merienne, Marc
Moreau, Thibaut
Papeix, Caroline
机构
[1] Univ Nice Cote dAzur, CHU Nice Pasteur, CRCSEP Cote dAzur, Nice, France
[2] Hosp Civils Lyon, Serv Neurol Sclerose Plaques Pathol Myelin & Neur, 59 Blvd Pinel, F-69677 Bron, France
[3] INSERM 1028, Ctr Rech Neurosci Lyon, Observ Francais Sclerose Plaques, F-69003 Lyon, France
[4] CNRS UMR 5292, F-69003 Lyon, France
[5] Univ Lyon, Univ Claude Bernard Lyon 1, F-69000 Lyon, France
[6] Eugene Dev EDMUS Fdn Multiple Sclerosis, F-69677 Bron, France
关键词
Multiple sclerosis; Immunization; Vaccine; Infection; Prevention; HEPATITIS-B VACCINATION; BACILLE-CALMETTE-GUERIN; INFLUENZA VACCINE; RISK-FACTORS; DEMYELINATING DISEASES; IMMUNE-RESPONSE; ANTIBODY-RESPONSE; CONTROLLED-TRIAL; RELAPSE; MS;
D O I
10.1016/j.msard.2019.04.004
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: To establish recommendations on immunization for patients with multiple sclerosis (MS) Background: Vaccines have been suspected in the past to trigger MS and relapses. With the extension of the immunoactive treatment arsenal, other concerns have been raised more recently about an increased risk of infection or a decreased effectiveness of immunization in immunosuppressed patients. Methods: The French Group for Recommendations into Multiple Sclerosis (France4MS) performed a systematic search of papers in Medline and other university databases (January 1975-June 2018). The RAND/UCLA appropriateness method was chosen to review the scientific literature and to formalize the degree of agreement among experts on 5 clinical questions related to immunization and MS. Readers from the steering committee conducted a systematic analysis, wrote a critical synthesis and prepared a list of proposals that were evaluated by a rating group of 28 MS experts. The final version of the recommendations was finally reviewed by a reading group of 110 health care professionals and classified as appropriate, inappropriate or uncertain. Results: Neurologists should verify the vaccination status as soon as MS is diagnosed and before disease-modifying treatments (DMTs) are introduced. The French vaccination schedule applies to MS patients and seasonal influenza vaccination is recommended. In the case of treatment-induced immunosuppression, MS patients should be informed about the risk of infection and the vaccination standards of the French High Council of Health should be applied. Live attenuated vaccines are contra-indicated in patients recently treated with immunosuppressive drugs, including corticosteroids; other vaccines can be proposed whatever the treatment, but their effectiveness may be partly reduced with some drugs. Conclusion: Physicians and patients should be aware of the updated recommendations for immunizations of patients with MS.
引用
收藏
页码:173 / 188
页数:16
相关论文
共 63 条
[1]   Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations [J].
Ahlgren, C. ;
Oden, A. ;
Toren, K. ;
Andersen, O. .
ACTA NEUROLOGICA SCANDINAVICA, 2009, 119 (05) :313-320
[2]   Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme [J].
Angelo, Maria-Genalin ;
David, Marie-Pierre ;
Zima, Julia ;
Baril, Laurence ;
Dubin, Gary ;
Arellano, Felix ;
Struyf, Frank .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (05) :466-479
[3]  
[Anonymous], 2001, RAND UCLA APPROPRIAT
[4]  
[Anonymous], 2004, AUDITION PUBLIQUE VA
[5]  
[Anonymous], 2012, BILAN PHARMACOVIGILA
[6]  
[Anonymous], 2018, CAL VACC REC VACC 20
[7]   Hepatitis B vaccination and the risk of multiple sclerosis [J].
Ascherio, A ;
Zhang, SM ;
Hernán, MA ;
Olek, MJ ;
Coplan, PM ;
Brodovicz, K ;
Walker, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (05) :327-332
[8]   Multiple sclerosis in India: A case-control study of environmental exposures [J].
Bansil, S ;
Singhal, BS ;
Ahuja, GK ;
Riise, T ;
Ladiwala, U ;
Behari, M ;
Cook, SD .
ACTA NEUROLOGICA SCANDINAVICA, 1997, 95 (02) :90-95
[9]   Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens [J].
Bar-Or, Amit ;
Wiendl, Heinz ;
Miller, Barry ;
Benamor, Myriam ;
Truffinet, Philippe ;
Church, Meg ;
Menguy-Vacheron, Francoise .
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2015, 2 (02) :e70
[10]   Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis [J].
Bar-Or, Amit ;
Freedman, Mark S. ;
Kremenchutzky, Marcelo ;
Menguy-Vacheron, Francoise ;
Bauer, Deborah ;
Jodl, Stefan ;
Truffinet, Philippe ;
Benamor, Myriam ;
Chambers, Scott ;
O'Connor, Paul W. .
NEUROLOGY, 2013, 81 (06) :552-558